Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Deyanira Corzo, MD, James Reeves, MD

Blood (2011) 118 (21): 478.

https://doi.org/10.1182/blood.V118.21.478.478

Published: 2011

Journal Articles

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Hui Huang, PhD, MBA, Sanggyu Choi, PhD, Deyanira Corzo, MD

Blood (2011) 118 (21): 1864.

https://doi.org/10.1182/blood.V118.21.1864.1864

Published: 2011

Journal Articles

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert M. Rifkin, MD, Nashat Y Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf A Gaffar, MD, Thomas A. Warr, MD, Rachel Neuwirth, MS, Deyanira Corzo, MD, James A Reeves, MD

Blood (2010) 116 (21): 619.

https://doi.org/10.1182/blood.V116.21.619.619

Published: 2010

Journal Articles

Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study

Blood (2010) 116 (21): 3026.

https://doi.org/10.1182/blood.V116.21.3026.3026

Published: 2010

Journal Articles

TROPICS 1: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Central Venous Catheters.

Nashat Gabrail, MD, Eric Sandler, MD, Veena Charu, MD, Nick Anas, MD, Eduardo Lim, MD, Martha Blaney, PharmD, Mark Ashby, PhD, Barbara S Gillespie, MD, Susan M Begelman, MD

Blood (2009) 114 (22): 173.

https://doi.org/10.1182/blood.V114.22.173.173

Published: 2009

Journal Articles

Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.

Ruben Niesvizky, James Reeves, Ian W Flinn, Robert M. Rifkin, Billy Clowney, Nashat Gabrail, Vijay R. Phooshkooru, Veena Charu, Christopher H. Chay, Deyanira Corzo, Rachel Neuwirth, Robert F. Manges, Thomas A. Warr

Blood (2009) 114 (22): 129.

https://doi.org/10.1182/blood.V114.22.129.129

Published: 2009

Journal Articles

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.

Veena Charu, MD, Victor Moyo, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc

Blood (2007) 110 (11): 3769.

https://doi.org/10.1182/blood.V110.11.3769.3769

Published: 2007

Journal Articles

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA).

Veena Charu, MD, Victor Moyo, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc

Blood (2007) 110 (11): 3770.

https://doi.org/10.1182/blood.V110.11.3770.3770

Published: 2007

Journal Articles

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Lee Schwartzberg, MD, Timothy Rearden, MD, Lorrin Yee, MD, Barry Mirtsching, MD, Veena Charu, MD, Hung Lam, PhD, Tom Lillie, MD/PhD, Ronald Burkes, MD, Peter Silberstein, MD

Blood (2006) 108 (11): 1306.

https://doi.org/10.1182/blood.V108.11.1306.1306

Published: 2006

Journal Articles

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia.

Kerry Taylor, MD, Peter Ganly, MD, Veena Charu, MD, Joseph DiBenedetto, MD, Karolyn Kracht, PhD, Greg Rossi, PhD, Enrique Hernandez, MD

Blood (2005) 106 (11): 3556.

https://doi.org/10.1182/blood.V106.11.3556.3556

Published: 2005

Journal Articles

First-Cycle Pegfilgrastim Reduces Chemotherapy-Induced Febrile Neutropenia among Older Patients with NHL Treated in Community Practice: Results from a Large, Randomized, Controlled Trial.

William Ershler, MD, Jennifer Tam, Veena Charu, MD, Ali Ben-Jacob, MD, Seta Shahin, Jeannette Green, Roger Dansey, MD, Lodovico Balducci, MD

Blood (2005) 106 (11): 4286.

https://doi.org/10.1182/blood.V106.11.4286.4286

Published: 2005

Journal Articles

Pegfilgrastim (Neulasta®) and Filgrastim (Neupogen®) Use in Patients Receiving Chemotherapy in Oncology Practices: Interim Results of the Assessment of Current CSF Evaluation for Proper Therapy (ACCEPT) Study.

Luis Alberto Meza, MD, Veena Charu, MD, Roger Dansey, MD, Fang Xie, PhD, Bradley Stolshek, PharmD

Blood (2004) 104 (11): 5309.

https://doi.org/10.1182/blood.V104.11.5309.5309

Published: 2004

NARROW

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study

TROPICS 1: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Central Venous Catheters.

Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.

Early vs Standard Intervention with an Extended Epoetin alfa (EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger Patients in a Randomized Clinical Trial.

Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U) Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in Chemotherapy-Induced Anemia (CIA).

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia.

First-Cycle Pegfilgrastim Reduces Chemotherapy-Induced Febrile Neutropenia among Older Patients with NHL Treated in Community Practice: Results from a Large, Randomized, Controlled Trial.

Pegfilgrastim (Neulasta®) and Filgrastim (Neupogen®) Use in Patients Receiving Chemotherapy in Oncology Practices: Interim Results of the Assessment of Current CSF Evaluation for Proper Therapy (ACCEPT) Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only